|
|
| | Glycinamide, L-prolyl-N-methyl-D-leucyl-, monohydrochloride Basic information |
| | Glycinamide, L-prolyl-N-methyl-D-leucyl-, monohydrochloride Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO |
| | Glycinamide, L-prolyl-N-methyl-D-leucyl-, monohydrochloride Usage And Synthesis |
| Uses | Pareptide monohydrochloride is a melanotropin-inhibiting factor (MIF) metabolically stable analogue. | | in vivo | Chronic coadministration of Pareptide (0.25 mg/kg, SC, BID, 3.5 days) to mice pretreated with Haloperidol (8.0 mg/kg, IP, BID, 3 days) significantly increases the cataleptic effects of a smaller challenge dose of Haloperidol (2.0 mg/kg, IP) given 15 hours after the last pretreatment injections (p<0.01)[1]. | | References | [1] Mycroft FJ, et al. Pro-Leu-Gly-NH2 and Pareptide inhibit development of tolerance to Haloperidol catalepsy in the mouse. Peptides. 1984 Sep-Oct;5(5):883-7. DOI:10.1016/0196-9781(84)90111-6 |
| | Glycinamide, L-prolyl-N-methyl-D-leucyl-, monohydrochloride Preparation Products And Raw materials |
|